These results demonstrate that WA targets macrophages to treat GalN/LPS-induced FH, which further support the possibility of targeting hepatic macrophage to treat liver disease36 and support the potential of WA to be repurposed as a hepatoprotective agent against the clinical FH, particularly featured with TNF-α-related apoptosis. The gene discussed is GAL; the disease is familial hyperaldosteronism.